腎臓・泌尿器用デバイスの世界市場-2022-2029

市場の概要

世界の腎臓・泌尿器用デバイス市場は、2021年に50億1563万米ドルとなり、2029年には159億4792万米ドルに達すると予測され、予測期間（2022-2029年）の年平均成長率は15.68%で推移するとされています。

幹細胞は、細胞分裂によって無限に自己再生することができる未分化な細胞です。また、これらの細胞は、特定の機能を持つより成熟した細胞へと区別することができます。現在、幹細胞は80以上の厄介な病気の治療に使われています。腎臓・泌尿器用デバイスは、幹細胞やその他の免疫系細胞を収集し、抽出し、凍結保存することで、将来の医療利用の可能性を探っています。

市場力学

これらの診断用製品の需要が増加している背景には、幹細胞の治療可能性に対する認識が高まっていることがあります。また、新規技術の進歩や研究開発費の増加も、市場の成長を後押しする要因となっています。これらすべての要因が市場成長の原動力となることが期待されます。

新規製品の上市数の増加や研究開発の高まりは、市場成長の原動力となるでしょう。

腎臓・泌尿器用デバイスの世界市場は、主に幹細胞の治療可能性に対する認識が高まっていることが要因となっています。また、幹細胞の保存、加工、保管に関する新しい技術の進歩も、市場の成長を後押しする要因となっています。造血幹細胞移植の増加や、幹細胞を用いた研究への投資の増加が、腎臓・泌尿器用デバイスの成長をさらに後押ししています。新興国、主要疾患の世界の負担の増加、新生児の数の多さ、GDP成長率の伸び、可処分所得は、主要プレイヤーにとって市場機会として作用します。例えば、2021年9月、幹細胞バンクと診断ソリューションのプロバイダーであるLifeCellは、同社の新規治療法であるMesocelが、インドのDGCI（Drug Controller General）からCOVID-19治療のための臨床試験の承認を取得したと発表しました。Mesocelは、提供された臍帯組織から得られた間葉系幹細胞から抽出されたものです。これにより、生命を脅かすCOVID-19肺炎や急性呼吸困難の患者さんの治療が可能になりました。臨床試験は2期に分けて実施する予定です。

様々な資金調達、斬新な技術の進歩、最新の革新的な製品の発売数が増加しており、これらの腎臓・泌尿器用デバイスの高い需要に繋がっています。例えば、2021年3月、腎臓・泌尿器デバイスのLifeCell社は、LifeCellレジストリ内でマッチング可能な幹細胞ユニットの正確な品質と数に関する情報を提供するとして、銀行会員コミュニティ向けに初のサービス「StemMatch」を開始しました。

腎臓・泌尿器用デバイスにかかる高い治療費と運用費が市場成長の妨げとなります。

しかし、腎臓・泌尿器用デバイスの高い運用コストや幹細胞採取時の法的・倫理的問題、厳しい規制の枠組みや受容・認知度の低さが、市場の進展を阻害する可能性があります。これらの幹細胞治療にかかる費用の高さが、市場の成長を妨げています。幹細胞治療の革新的なクリニックであるDVC Stemによると、IRBの承認を受けた同社の間葉系幹細胞（MSC）プロトコルは、約25,000米ドルの費用がかかるとされています。

COVID-19の影響分析

パンデミックは、世界の財務的な期待、業務、危機対応戦略にマイナスの影響を及ぼしました。COVID-19の発生は、ヘルスケア産業に深刻な影響を及ぼしています。腎臓・泌尿器科機器市場は、COVIDに関心が向けられたためにすべての研究や臨床試験に影響が及び、COVIDによって莫大な損失を経験しました。しかし現在、市場参入企業は、研究市場を活用し、パンデミックに対抗するための最先端のアイテムを生み出すことで、長期的・短期的な成長戦略を変えつつあります。様々な取り組み、コラボレーション、合併が世界中で起こっており、市場の成長を後押ししています。例えば、2022年8月、臍帯血再生治療薬を製造するStemCyte社は、臍帯血幹細胞療法を用いたポストCOVID症候群の第2相臨床試験が米国食品医薬品局から承認を得たと発表しました。

目次

第1章 市場調査手法とスコープ

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 市場影響要因
  • 促進要因
    • 新製品上市の増加
    • 研究開発の増加
  • 抑制要因
    • 幹細胞治療に伴う高コスト
  • ビジネスチャンス
  • 影響分析

第5章 産業分析

• ポーターの5つの力
• アンメットニーズ
• サプライチェーン分析
• 規制分析

第6章 COVID-19分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的取り組み
• まとめ

第7章 タイプ別

• 人工透析装置
• 尿路結石治療器
• 尿失禁・骨盤臓器脱装置
• 前立腺肥大症治療器
• 内視鏡機器
• その他

第8章 アプリケーション別

• 腎臓疾患
• 膀胱疾患
• 泌尿器がん
• その他

第9章 エンドユーザー別

• 病院
• 専門センター
• 外来外科センター
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• 製品ベンチマーク
• 注目の主要企業リスト

第12章 企業プロファイル

• Medtronic Plc
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Baxter International, Inc.
• Asahi Kasei Corporation
• B.Braun Group
• Boston Scientific Corporation
• Coloplast AS
• Dornier MedTech
• Terumo Corporation
• Fresenius Medical Care
• Nipro Corporation

第13章 腎臓・泌尿器用デバイスの世界市場-DataM

Market Overview

The global Nephrology and Urology Devices market was valued at US$ 5,015.63 million in 2021 and is estimated to reach US$ 15,947.92 million by 2029, growing at a CAGR of 15.68% during the forecast period (2022-2029).

Stem cells are undifferentiated cells that can self-renew indefinitely through cell division. These cells can also be distinguished into more mature cells with specific functions. Currently, stem cells are used to treat more than 80 nasty diseases. Nephrology and Urology Devices is collecting, extracting and storing by cryogenically freezing the stem cells and other immune system cells for potential future medical use.

Market Dynamics

The increasing demand for these diagnostic products is due to the growing awareness of the therapeutic potential of stem cells. Other factors aiding the market growth are the advancements in novel technologies and increasing research and development expenditure. All these factors are expected to drive market growth.

The increasing number of novel product launches and the rising research and development will drive market growth.

The global market for Nephrology and Urology Devices is primarily driven by the growing awareness of the therapeutic potential of stem cells. Other factors aiding the market growth are advancements in novel stem cell preservation, processing, and storage technologies. The rise in hematopoietic stem cell transplantation procedures and increasing investments in stem cell-based research further propel Nephrology and Urology Devices. Emerging countries, the rising global burden of major diseases, the large number of newborns, the growth in GDP growth, and disposable income act as market opportunities for key players. For instance, in Sep 2021, LifeCell, a stem cell bank and provider of diagnostic solutions, announced that its novel therapy, Mesocel, got approved for a clinical trial from DGCI, the Drug Controller General of India, for COVID-19 treatment. Mesocel is extracted from mesenchymal stem cells derived from the donated umbilical cord tissue. This can now be used to treat patients with life-threatening COVID-19 pneumonia or acute respiratory distress. The clinical trial will be conducted in 2 phases.

Various funding, novel technological advancements, and the number of the latest, innovative product launches are increasing, leading to the high demand for these Nephrology and Urology Devices. For instance, in Mar 2021, LifeCell, a Nephrology and Urology Devices company, launched StemMatch, a first-of-its-kind service for the banking members community as it gives information on the accurate quality and number of stem cell units that are matching available within the LifeCell registry.

The high therapy and operational costs associated with Nephrology and Urology Devices will hamper the market's growth.

However, the high operational costs of Nephrology and Urology Devices and legal and ethical issues during the collection of stem cells, along with stringent regulatory frameworks and lack of acceptance and awareness, may hinder the market progress. The high cost of these stem cell therapies is hindering the market growth. According to DVC Stem, an innovative clinic of stem cell therapy, its mesenchymal stem cell (MSC) protocol that is IRB approved costs around US$25,000.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The Nephrology and Urology Devices market has experienced huge losses due to COVID, as all the research and clinical trials got affected due to the diversion of attention toward COVID. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Various initiatives, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in Aug 2022, StemCyte, a company manufacturing cord blood regenerative therapeutic, announced that Post-COVID Syndrome's Phase II clinical trial with the help of umbilical cord blood stem cell therapy got approved by U.S. Food and Drug Administration.

Segment Analysis

The umbilical cord-derived stem cells segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The umbilical cord-derived stem cells (UCSTs) segment is the highest market holder in the global Nephrology and Urology Devices market. Cord Blood is affluent in stem cells. Stem cells are developed in the bone marrow and differentiate into different blood cells, which are important in various therapies related to blood disorders, such as sickle cell disease. Umbilical cord blood can be used for gene therapy or transplantation as it's a hematopoietic stem cell Type. Umbilical cord-derived mesenchymal stem cells can be used for inflammatory and immune disease therapy. These can be promising active substances for therapeutic product development as they have a few issues related to safety, availability and ethics.

Umbilical cord-derived stem cells dominate the market due to the rising birth rate and global chronic disease cases. According to the Centre for Disease Control and Prevention, in 2021, approximately 3,659,289 newborn cases were reported in the United States. The rising number of people suffering from blood-related disorders, regulatory approvals and growing technological advancements or research/clinical trial studies drive the market's growth. For instance, in May 2021, Cordlife Group Limited, 1st private cord blood bank in Singapore, entered into a partnership with SingHealth Duke-NUS Academic Medical Centre to test new technology that can increase blood-forming stem cells in number from stored umbilical cord blood that is stored in the first-in-man study in Singapore.

Geographical Analysis

North America holds the largest market share of the global Nephrology and Urology Devices market.

North America dominates the global Nephrology and Urology Devices market, primarily attributed to the rising prevalence of chronic ailments such as leukemia, thalassemia, diabetes, autism and many more due to changing environments worldwide, established healthcare infrastructure, and higher investment in R&D activities contribute to North America's rapid share growth. Moreover, its broad base patient population also contributes to the growth of its share. According to the American Cancer Society, in 2022, Around 60.650 estimated novel leukemia cases will occur, out of which 24,000 deaths will occur in the United States.

Moreover, the growing number of product launches is responsible for the market's growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market's growth. Many key developments, technological advancements, collaborations and agreements are taking place in this region. For instance, in Feb 2021, American CryoStem Corporation, a biotechnology company at the clinical stage working on autologous cellular therapies, announced its agreement with BioTherapeutics Labs Corp., a company manufacturing umbilical cord tissues that's also FDA-registered.

Competitive Landscape

The Nephrology and Urology Devices market is highly competitive with local and global companies' presence. Medtronic Plc, Baxter International, Inc., Asahi Kasei Corporation, B.Braun Group, Boston Scientific Corporation, Coloplast AS, Dornier MedTech, Terumo Corporation, Fresenius Medical Care, Nipro Corporation and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in May 2022, Medtronic announced the data that shows the advantages of simple blood pressure procedures of symplicity spyral renal denervation system for achieving a targeted range of levels of blood pressure.

Medtronic Plc:

Overview:

Medtronic is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The Company has two operating divisions. It focuses on hematology, immunology, neuroscience, ophthalmology, cardiovascular, respiratory & allergy, and solid tumors. It was established in 1949 and is headquartered in Dublin, Ireland.

Product Portfolio:

MaxCell: MaxCell is StemCyte's proprietary processing method that retains the stem cells in higher volume. It preserves more total nucleated cells than other standard processing procedures, improving engraftment chances.

Key Development: In May 2022, Medtronic and DaVita Inc. announced their intention to make a novel, independent medical device company that will focus on kidney care to increase the treatment experience of patients.

The global Nephrology and Urology Devices market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The rising novel product launches
    • 4.1.1.2. Increasing research and development
  • 4.1.2. Restraints:
    • 4.1.2.1. High cost associated with stem cell therapies
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces
• 5.2. Unmet Needs
• 5.3. Supply chain Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Dialysis devices *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Urinary stone treatment devices
• 7.4. Urinary incontinence & pelvic organ prolapse devices
• 7.5. Benign prostatic hyperplasia (BPH) treatment devices
• 7.6. Endoscopy devices
• 7.7. Others

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Kidney Disease *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Bladder Disorder
• 8.4. Urological Cancer
• 8.5. Others

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospitals *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Specialty Centres
• 9.4. Ambulatory Surgical Centres
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking
• 11.4. List of Key Companies to Watch

12. Company Profiles

• 12.1. Medtronic Plc
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Baxter International, Inc.
• 12.3. Asahi Kasei Corporation
• 12.4. B.Braun Group
• 12.5. Boston Scientific Corporation
• 12.6. Coloplast AS
• 12.7. Dornier MedTech
• 12.8. Terumo Corporation
• 12.9. Fresenius Medical Care
• 12.10. Nipro Corporation

LIST NOT EXHAUSTIVE

13. Global Nephrology and Urology Devices Market- DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us